Prospective Multicenter Study of Pegylated Liposomal Doxorubicin Treatment in Patients With Advanced or Refractory Mycosis Fungoides or Sézary Syndrome
G. Quéreux(Nantes Université), Brigitte Dréno(Nantes Université), M. Beylot‐Barry(Université de Bordeaux), O. Dereure(Beth Israel Deaconess Medical Center), Ludovic Martin, Jean‐Michel Nguyen(Inserm), Bruno Sasolas, Elisabeth Puzenat, P. Joly(Inserm), Sónia M Ribeiro Marques, P. Vabres(CHU Dijon Bourgogne), Florent Grange(Hôpital Lyon Sud), M. Delaunay(Hôpital Larrey), Christophe Bédane, M. D’Incan(Centre Hospitalier Universitaire de Clermont-Ferrand), Amir Khammari(Inserm), A Claudy, P. Celérier(Centre Hospitalier de La Rochelle)
Cited by 103
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k